Bladder cancer is a heterogeneous malignancy and is responsible for approximately 3.2%
of new diagnoses of cancer per year (Sung et al., 2021). Fibroblast Growth Factor Receptors …

Fibroblast growth factor (FGF) signalling via FGF receptors (FGFR1–4) orchestrates fetal
development and contributes to tissue and whole-body homeostasis, but can also promote …

There are five fibroblast growth factor receptors (FGFRs), namely, FGFR1–FGFR5. When
FGFR binds to its ligand, namely, fibroblast growth factor (FGF), it dimerizes and …

Despite recent advances, advanced-stage urothelial carcinoma (aUC) remains incurable,
with 5-year survival rates of approximately 10%. Platinum-based chemotherapy has a major …

ABSTRACT Fibroblast Growth Factor (FGF) ligands and their receptors are crucial factors
driving chemoresistance in several malignancies, challenging the efficacy of currently …

Several fibroblast growth factor receptor (FGFR) inhibitors are approved or in clinical
development for the treatment of FGFR-driven urothelial cancer, and molecular mechanisms …

The treatment of metastatic urothelial carcinoma has dramatically changed over the past
decade with the approval of several therapies from multiple drug classes including immune …

Cholangiocarcinomas and urothelial carcinomas are lethal tumors worldwide and only a
minority of patients are eligible for surgery at diagnosis. Moreover, patients are poorly …

Simple Summary Urothelial carcinoma is a malignancy of the cells lining the genitourinary
tract but it most commonly occurs in the bladder. Once urothelial carcinoma has spread …

Background and objective The 2024 US Food and Drug Administration approval of
erdafitinib for the treatment of metastatic urothelial carcinoma (mUC) with FGFR3 alterations …